The United States Food and Drug Administration’s Platform Technology Designation to Expedite the Development of Drugs DOI Creative Commons
Sarfaraz K. Niazi

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(7), P. 918 - 918

Published: July 10, 2024

Drug development costs can be significantly reduced if proven “platform” technologies are allowed to used without having validate their use. The most recent US Food and Administration (FDA) guideline brings more clarity, as well a greater focus on the complex that now for faster drug development. FDA has highlights use of lipid nanoparticles (LNPs) package deliver mRNA vaccines, gene therapy, short (2–20 length) synthetic nucleotides (siRNA). Additionally, monoclonal antibody cell is targeted. provides systematic process requesting platform status benefit from its advantages. It advanced science rationality into regulatory steps FDA’s approval drugs biologicals.

Language: Английский

Lipid-based nanoparticles to address the limitations of GBM therapy by overcoming the blood-brain barrier, targeting glioblastoma stem cells, and counteracting the immunosuppressive tumor microenvironment DOI Creative Commons
Changhong Zhao,

Xinshu Zhu,

Jianmei Tan

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 171, P. 116113 - 116113

Published: Jan. 5, 2024

Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor, characterized by high heterogeneity, strong invasiveness, poor prognosis, and a low survival rate. A broad range of nanoparticles have been recently developed as drug delivery systems for GBM therapy owing to their inherent size effect ability cross blood-brain barrier (BBB). Lipid-based (LBNPs), such liposomes, solid lipid NPs (SLNs), nano-structured carriers (NLCs), emerged promising system treatment because unique size, surface modification possibilities, proven bio-safety. In this review, main challenges current clinical strategies on how novel LBNPs overcome them were explored. The application progress LBNP-based in chemotherapy, immunotherapy, gene recent years systematically reviewed, prospect was discussed.

Language: Английский

Citations

31
Microenvironment-based immunotherapy in oral cancer: a comprehensive review DOI

Hassan Mivehchi,

Aisan Eskandari-Yaghbastlo,

Masumeh Ghazanfarpour

et al.

Medical Oncology, Journal Year: 2025, Volume and Issue: 42(5)

Published: March 28, 2025

Language: Английский

Citations

2
Car T Cells in Solid Tumors: Overcoming Obstacles DOI Open Access
Joselyn Rojas, María P. Díaz, Jim Palmar

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(8), P. 4170 - 4170

Published: April 10, 2024

Chimeric antigen receptor T cell (CAR cell) therapy has emerged as a prominent adoptive and therapeutic approach of great interest in the fight against cancer. This shown notorious efficacy refractory hematological neoplasm, which bolstered its exploration field solid cancers. However, successfully managing tumors presents considerable intrinsic challenges, include necessity guiding modified cells toward tumoral region, assuring their penetration survival adverse microenvironments, addressing complexity identifying specific antigens for each type review focuses on outlining challenges faced by CAR when used treatment tumors, well presenting optimizations emergent approaches directed at improving this particular context. From precise localization to modulation microenvironment adaptation recognition strategies, diverse pathways will be examined overcome current limitations buttress potential tumors.

Language: Английский

Citations

13
The next frontier in immunotherapy: potential and challenges of CAR-macrophages DOI Creative Commons
Jing Li,

Ping Chen,

Wenxue Ma

et al.

Experimental Hematology and Oncology, Journal Year: 2024, Volume and Issue: 13(1)

Published: Aug. 5, 2024

Abstract Chimeric antigen receptor macrophage (CAR-MΦ) represents a significant advancement in immunotherapy, especially for treating solid tumors where traditional CAR-T therapies face limitations. CAR-MΦ offers promising approach to target and eradicate tumor cells by utilizing macrophages’ phagocytic antigen-presenting abilities. However, challenges such as the complex microenvironment (TME), variability expression, immune suppression limit their efficacy. This review addresses these issues, exploring mechanisms of action, optimal construct designs, interactions within TME. It also delves into ex vivo manufacturing CAR-MΦ, discussing autologous allogeneic sources importance stringent quality control. The potential synergies integrating with existing cancer like checkpoint inhibitors conventional chemotherapeutics are examined highlight possible enhanced treatment outcomes. Furthermore, regulatory pathways scrutinized alongside established protocols cells, identifying unique considerations essential clinical trials market approval. Proposed safety monitoring frameworks aim manage adverse events, cytokine release syndrome, crucial patient safety. Consolidating current research insights, this seeks refine therapeutic applications, overcome barriers, suggest future directions transition from experimental platforms standard care options.

Language: Английский

Citations

12
PRMT1 in human neoplasm: cancer biology and potential therapeutic target DOI Creative Commons

Shiquan Shen,

Honglong Zhou,

Zongyu Xiao

et al.

Cell Communication and Signaling, Journal Year: 2024, Volume and Issue: 22(1)

Published: Feb. 8, 2024

Abstract Protein arginine methyltransferase 1 (PRMT1), the predominant type I protein methyltransferase, plays a crucial role in normal biological functions by catalyzing methylation of side chains, specifically monomethylarginine (MMA) and asymmetric dimethylarginine (ADMA), within proteins. Recent investigations have unveiled an association between dysregulated PRMT1 expression initiation progression tumors, significantly impacting patient prognosis, attributed to PRMT1’s involvement regulating various facets tumor cell biology, including DNA damage repair, transcriptional translational regulation, as well signal transduction. In this review, we present overview recent advancements research across different types, with specific focus on its contributions proliferation, metastasis, invasion, drug resistance. Additionally, expound dynamic during distinct stages cancer progression, elucidating unique regulatory mechanisms same signaling pathway distinguishing promotive inhibitory effects. Importantly, sought provide comprehensive summary analysis progress contributing deeper understanding tumorigenesis, development, potential treatment strategies.

Language: Английский

Citations

9
Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy DOI Creative Commons
Anna De Lucia, L. Mazzotti, Anna Gaimari

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: Feb. 10, 2025

Over the past decades, significant progress has been made in understanding of non-small cell lung cancer (NSCLC) biology and tumor progression mechanisms, resulting development novel strategies for early detection wide-ranging care approaches. Since their introduction, over 20 years ago, targeted therapies with tyrosine kinase inhibitors (TKIs) have revolutionized treatment landscape NSCLC. Nowadays, remain gold standard many patients, but still they suffer from adverse effects, including unexpected toxicity intrinsic acquired resistance mutations, which lead to relapse. The adoption immune checkpoint (ICIs) 2015, offered exceptional survival benefits patients without targetable alterations. Despite this notable progress, challenges remain, as not all respond favorably ICIs, therapy can develop time. A crucial factor influencing clinical response immunotherapy is microenvironment (TME). TME pivotal orchestrating interactions between neoplastic cells system, growth outcomes. In review, we discuss how intricate relationship success survey current state intervention, a focus on forthcoming promising chimeric antigen receptor (CAR) T sets major obstacles CAR-T therapies, creating conditions that suppress response, inducing exhaustion. To enhance efficacy, specific efforts associated NSCLC, should definitely TME-related immunosuppression escape by combining blockades.

Language: Английский

Citations

1
Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence DOI Creative Commons
Muhammad Tufail, Canhua Jiang, Ning Li

et al.

Military Medical Research, Journal Year: 2025, Volume and Issue: 12(1)

Published: Feb. 11, 2025

Abstract Cancer recurrence, driven by the phenomenon of tumor dormancy, presents a formidable challenge in oncology. Dormant cancer cells have ability to evade detection and treatment, leading relapse. This review emphasizes urgent need comprehend dormancy its implications for recurrence. Despite notable advancements, significant gaps remain our understanding mechanisms underlying lack reliable biomarkers predicting provides comprehensive analysis cellular, angiogenic, immunological aspects dormancy. It highlights current therapeutic strategies targeting dormant cells, particularly combination therapies immunotherapies, which hold promise preventing By elucidating these proposing innovative research methodologies, this aims deepen ultimately facilitating development more effective recurrence improving patient outcomes.

Language: Английский

Citations

1
CAR T Cells in Lung Cancer: Targeting Tumor-Associated Antigens to Revolutionize Immunotherapy DOI
Sattam Khulaif Alenezi

Pathology - Research and Practice, Journal Year: 2025, Volume and Issue: unknown, P. 155947 - 155947

Published: March 1, 2025

Language: Английский

Citations

1
Chimeric Antigen Receptor (CAR)-T Cell Therapy for Non-Hodgkin’s Lymphoma DOI Creative Commons
Maria Florencia Giraudo, Zachary Jackson, Indrani Das

et al.

Pathogens and Immunity, Journal Year: 2024, Volume and Issue: 9(1), P. 1 - 17

Published: March 15, 2024

This review focuses on the use of chimeric antigen receptor (CAR)-T cell therapy to treat non-Hodgkin’s lymphoma (NHL), a classification heterogeneous malignant neoplasms lymphoid tissue. Despite various conventional and multidrug chemotherapies, poor prognosis for NHL patients remains has prompted utilization groundbreaking personalized therapies such as CAR-T cells. cells are T engineered express CAR that enables specifically lyse tumor with extracellular expression choice. A is composed an antibody fragment or target protein binding domain conjugated activating intracellular signaling motifs common In general, designed recognize cellular markers ubiquitously expressed B CD19+, CD20+, CD22+. Clinical trials using ZUMA-7 TRANSFORM demonstrated promising results compared standard care ultimately led FDA approval treatment relapsed/refractory NHL. success NHL, challenges include adverse side effects well extrinsic intrinsic mechanisms resistance lead suboptimal outcomes. Overall, have improved clinical outcomes in generated optimism around their future applications.

Language: Английский

Citations

8
Promising Therapeutic Strategies for Hematologic Malignancies: Innovations and Potential DOI Creative Commons
Jan Jakub Lica, Bhaskar Pradhan, Kawthar Safi

et al.

Molecules, Journal Year: 2024, Volume and Issue: 29(17), P. 4280 - 4280

Published: Sept. 9, 2024

In this review we explore innovative approaches in the treatment of hematologic cancers by combining various therapeutic modalities. We discuss synergistic potential inhibitors targeting different cellular pathways with immunotherapies, molecular therapies, and hormonal therapies. Examples include PI3K proteasome inhibitors, NF-κB immunotherapy checkpoint neddylation therapies tumor microenvironment. Additionally, use small molecules peptide cancer treatment. These multidimensional combinations present promising strategies for enhancing efficacy overcoming resistance mechanisms. However, further clinical research is required to validate their effectiveness safety profiles patients.

Language: Английский

Citations

8